4-n-butylresorcinol

01/01/2016 - "Furthermore, considering the fact that Indian skin is more prone to irritation with hypopigmenting agents, our study explores the efficacy, safety, and tolerability of 4-n-butylresorcinol 0.3% cream in Indian subjects with melasma. "
01/01/2016 - "Assessment of efficacy, safety, and tolerability of 4-n-butylresorcinol 0.3% cream: an Indian multicentric study on melasma."
02/01/2010 - "The aim of this study was to investigate the hypopigmenting efficacy and safety of 4-n-butylresorcinol 0.1% cream for the treatment of melasma. "
02/01/2010 - "The Efficacy and Safety of 4-n-butylresorcinol 0.1% Cream for the Treatment of Melasma: A Randomized Controlled Split-face Trial."
01/01/2016 - "Our data suggest that the 4-n-butylresorcinol 0.3% cream is safe, effective, and well tolerated in Indian patients with melasma."

01/01/2017 - "We used 4-n-butylresorcinol to treat human hyperpigmentation and found that sequential application of serum formulation and DMNs was successful. "
08/01/2020 - "Allergic contact dermatitis caused by 4-n-butylresorcinol present in a night cream for skin hyperpigmentation."
01/01/2013 - "4-n-butylresorcinol, a highly effective tyrosinase inhibitor for the topical treatment of hyperpigmentation."

08/01/2020 - "Allergic contact dermatitis caused by 4-n-butylresorcinol present in a night cream for skin hyperpigmentation."

01/01/2013 - "The resulting clinical improvement of skin hyperpigmentations reveals 4-n-butylresorcinol as a very valuable active compound for the management of pigmentation disorders."

06/01/2017 - "B16F10 melanoma cells were cultured in media containing α-MSH in the presence or absence of 4-n-butylresorcinol. "
06/01/2017 - "4-n-butylresorcinol enhances proteolytic degradation of tyrosinase in B16F10 melanoma cells."